BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9224607)

  • 1. Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
    Kuwabara T; Warashina M; Tanabe T; Tani K; Asano S; Taira K
    Nucleic Acids Res; 1997 Aug; 25(15):3074-81. PubMed ID: 9224607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M; Kuwabara T; Taira K
    Nucleic Acids Symp Ser; 1997; (37):213-4. PubMed ID: 9586075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences.
    Pachuk CJ; Yoon K; Moelling K; Coney LR
    Nucleic Acids Res; 1994 Feb; 22(3):301-7. PubMed ID: 8127665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H; Mills K; Gibson I
    Leukemia; 1996 Jun; 10(6):1054-64. PubMed ID: 8667643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
    Warashina M; Kuwabara T; Nakamatsu Y; Taira K
    Chem Biol; 1999 Apr; 6(4):237-50. PubMed ID: 10099134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes).
    Wu Y; Yu L; McMahon R; Rossi JJ; Forman SJ; Snyder DS
    Hum Gene Ther; 1999 Nov; 10(17):2847-57. PubMed ID: 10584930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of novel allosterically trans- and cis-activated connected maxizymes that are designed to suppress BCR-ABL expression.
    Hamada M; Kuwabara T; Warashina M; Nakayama A; Taira K
    FEBS Lett; 1999 Nov; 461(1-2):77-85. PubMed ID: 10561500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W; Daskalakis M; Finke J; Dölken G
    FEBS Lett; 1994 Jan; 338(2):175-8. PubMed ID: 8307177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosterically controlled single-chained maxizymes with extremely high and specific activity.
    Kuwabara T; Hamada M; Warashina M; Taira K
    Biomacromolecules; 2001; 2(3):788-99. PubMed ID: 11710033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activities of tRNA-embedded dimeric minizymes.
    Kuwabara T; Warashina M; Nakayama A; Ohkawa J; Taira K
    Nucleic Acids Symp Ser; 1997; (37):307-8. PubMed ID: 9586122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P; Wright LA; Milliken S; Biggs JC
    Exp Hematol; 1995 Aug; 23(9):986-9. PubMed ID: 7543419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP
    Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA; Milliken S; Biggs JC; Kearney P
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing of the secondary structure of maxizymes.
    Zhou JM; Nakamatsu Y; Kuwabara T; Warashina M; Tanaka Y; Yoshinari K; Taira K
    Nucleic Acids Symp Ser; 1999; (42):219-20. PubMed ID: 10780458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
    James HA; Twomey CM; Mills KI; Gibson I
    Biochem Soc Trans; 1996 Aug; 24(3):409S. PubMed ID: 8878953
    [No Abstract]   [Full Text] [Related]  

  • 20. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W
    Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.